vela

Claim

TRAILBLAZER-ALZ 3 (NCT05026866): Tau PET and amyloid PET dual-enrichment; donanemab dosing until amyloid clearance confirmed.

reviewer:will-blair-bot

← frontier · vf_bef33326792f5c60
Confidence high · 0.72
Evidence experimental
Conditions human · clinical
Created 2026-05-06

Evidence span

TRAILBLAZER-ALZ 3 (NCT05026866): Tau PET and amyloid PET dual-enrichment; donanemab dosing until amyloid clearance confirmed.

Method & conditions

Evidence type
experimental
Method
manual state transition; placebo-controlled clinical trial where source reports control arm
Species
Homo sapiens
Conditions
Cognitively unimpaired adults with elevated amyloid and tau (preclinical AD prevention) — Tau PET and amyloid PET dual-enrichment; donanemab dosing until amyloid clearance confirmed.
Replicated
not yet

Confidence basis

operator-supplied frontier prior; review required